MLTX
FDA says, ‘keep going’
MoonLake Immunotherapeutics got the kind of meeting outcome biotech investors love: the FDA didn’t throw a wrench into the plan. Instead, the company says its final pre-BLA meeting for sonelokimab in hidradenitis suppurativa ended with alignment on submission plans and label strategy.
That matters because pre-BLA meetings are basically the FDA’s way of saying, “Here’s what we expect before you bring us the big paperwork.” If the agency and the company are in sync, the path to filing gets a lot less messy. And in biotech, less messy is often worth a very loud stock pop.
Why the market cared
MoonLake’s shares jumped about 12.4% intraday, which is the market’s way of saying: “Okay, maybe this drug really does have a shot.” The company now expects to file its Biologics License Application by the end of September 2026, with potential approval and commercial launch eyed for the second half of 2027.
A few investor-relevant takeaways:
- The company says the FDA meeting was favorable, which lowers a bit of regulatory uncertainty.
- Sonelokimab remains the key asset to watch, especially in hidradenitis suppurativa.
- MoonLake ended March with $357.9 million in cash and marketable securities, which it says should fund operations into the end of 2027.
The biotech version of a green light
This doesn’t mean approval is in the bag — biotech is never that polite. But it does mean MoonLake just cleared an important checkpoint without public drama, and that’s enough to wake up the stock.
Big picture: for a company trading well below its 200-day moving average, a clean regulatory milestone can feel like oxygen. Whether that turns into a lasting trend is all about what comes next: the filing, the review, and whether the FDA stays friendly the whole way.